UBS Maintains Neutral on Sabra Health Care REIT, Lowers Price Target to $21

Benzinga Newsdesk www.benzinga.com Negative 76.8%

Neg 76.8% Neu 0% Pos 0%

UBS analyst Michael Goldsmith maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Neutral and lowers the price target from $22 to $21.